angioplasty

La ATC es una alternativa válida en el TCI

The Road Towards a “More Perfect” Angioplasty Is Already Being Traveled

The aim of revascularization, whether through angioplasty or surgery, is to restore adequate flow to the myocardium; that much is obvious. However, after millions of “successful” procedures with the best technology applied to drug-eluting stents and optimal medical treatment, we still have a high ratio of patients who experience new events. Could an optimal angiographical<a href="https://solaci.org/en/2019/11/11/the-road-towards-a-more-perfect-angioplasty-is-already-being-traveled/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | IVUS-XPL: 5-Year Follow-up for Angiography-vs. IVUS-Guided Angioplasty

Courtesy of SBHCI. The aim of this work, which was presented during the TCT 2019 Scientific Session and simultaneously published in JACC Intv, was to prove the benefit of intravascular ultrasound (IVUS) in angioplasty. The IVUS-XPL trial randomized 1400 patients with long coronary lesions (≥28 mm) to IVUS-guided angioplasty (n = 700) vs. angiography-guided angioplasty (n = 700). All procedures were<a href="https://solaci.org/en/2019/10/01/tct-2019-ivus-xpl-5-year-outcomes-from-a-randomized-trial-of-intravascular-ultrasound-guided-vs-angiography-guided-pci-of-long-coronary-lesions/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos&nbsp;Fava. Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3&nbsp;years. However, beyond such term, we had no valid information. Researchers analyzed the 5-year follow-up results for the<a href="https://solaci.org/en/2019/10/01/tct-2019-excel-5-year-outcomes-from-a-randomized-trial-of-pci-vs-cabg-in-patients-with-left-main-coronary-artery-disease/" title="Read more" >...</a>

ESC 2019 | CONDI-2ERIC-PPCI: punto final para el pre-acondicionamiento isquémico en angioplastia primaria

ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, according to this study presented on Sunday at the European Society of Cardiology Congress 2019. Prior studies were limited and small, but this analysis seems to provide definitive evidence with regard to ischemic pre-conditioning. The<a href="https://solaci.org/en/2019/09/05/esc-2019-condi-2eric-ppci-final-blow-against-ischemic-pre-conditioning-in-primary-angioplasty/" title="Read more" >...</a>

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

Angioplasty vs. Surgery in Lower Limb Ischemia

This analysis of data from an already published study, “Bypass Versus Angioplasty in Severe Ischemia of the Limb (BASIL-1),” confirms the superiority of bypass over balloon angioplasty, with or without stenting, in patients with chronic lower limb ischemia who require a femoropopliteal intervention. While analyzed interventions took place between 1999 and 2003 (a fact subject<a href="https://solaci.org/en/2019/08/23/angioplasty-vs-surgery-in-lower-limb-ischemia/" title="Read more" >...</a>

Peri-Procedural Infarction in Angioplasty vs. Surgery in the Left Main Coronary Artery

According to the EXCEL trial, peri-procedural infarction was more common after left main coronary artery surgery compared with angioplasty, and it was strongly associated with increased 3-year mortality after controlling all possible confounding variables. This increased mortality was only present in extensive infarctions with an increase in CK-MB ≥10×. The EXCEL trial seems to want<a href="https://solaci.org/en/2019/07/05/peri-procedural-infarction-in-angioplasty-vs-surgery-in-the-left-main-coronary-artery/" title="Read more" >...</a>

terapia antitrombótica triple

Antithrombotic Strategies in Atrial Fibrillation and Angioplasty

What is the most appropriate antithrombotic strategy for a patient with atrial fibrillation and coronary artery disease, particularly when admitted with acute coronary syndrome or undergoing coronary angioplasty? This is a question whose answer is still in the works and that literature is addressing dynamically. Whatever we read yesterday may already be out of date<a href="https://solaci.org/en/2019/06/26/antithrombotic-strategies-in-atrial-fibrillation-and-angioplasty/" title="Read more" >...</a>

EuroPCR 2019 | Las imágenes intravasculares son casi imprescindibles para planear una angioplastia

EuroPCR 2019 | Intravascular Imaging Almost Indispensable for Planning an Angioplasty

Cost and time are the two main enemies of intravascular imaging, but lack of expertise may also play a role. A new European Association of Percutaneous Cardiovascular Interventions (EAPCI) expert consensus statement released at EuroPCR 2019 argues that there is a need for more use of intracoronary imaging in settings of acute coronary syndromes and<a href="https://solaci.org/en/2019/05/27/europcr-2019-intravascular-imaging-almost-indispensable-for-planning-an-angioplasty/" title="Read more" >...</a>

ACC 2019 | STOPDAPT-2: Monoterapia con P2Y12 luego de un corto período de doble antiagregación post angioplastia

ACC 2019 | STOPDAPT-2: P2Y12 Monotherapy After Short-Term Dual Antiplatelet Therapy After Angioplasty

Aspirin is against the ropes: first, it was primary prevention; now, its use is being reconsidered even in relation to angioplasty. There might be paradigm changes as regards antiplatelet therapy after angioplasty. These two studies presented at the American College of Cardiology (ACC) 2019 Scientific Session can really change what we have been doing unquestioningly<a href="https://solaci.org/en/2019/03/25/acc-2019-stopdapt-2-p2y12-monotherapy-after-short-term-dual-antiplatelet-therapy-after-angioplasty/" title="Read more" >...</a>

ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination in Atrial Fibrillation and Angioplasty

Aspirin increases bleeding with no ischemic benefit, but a trend toward more stent thrombosis with placebo warrants further studies. Patients with atrial fibrillation who receive an anticoagulant agent and coronary angioplasty with a stent, and then continue with aspirin, experience an increased risk of bleeding without any ischemic benefit whatsoever. &nbsp; The use of a<a href="https://solaci.org/en/2019/03/25/acc-2019-augustus-apixaban-plus-p2y12-inhibitor-is-the-best-combination-in-atrial-fibrillation-and-angioplasty/" title="Read more" >...</a>

Top